Drucker Wealth 3.0 LLC Sells 15,443 Shares of Pfizer Inc. $PFE

Drucker Wealth 3.0 LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 18.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,503 shares of the biopharmaceutical company’s stock after selling 15,443 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Pfizer were worth $1,725,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of Pfizer by 6.9% in the second quarter. Aberdeen Group plc now owns 5,272,611 shares of the biopharmaceutical company’s stock worth $128,098,000 after purchasing an additional 338,461 shares during the last quarter. Lmcg Investments LLC increased its position in shares of Pfizer by 3.8% in the second quarter. Lmcg Investments LLC now owns 62,597 shares of the biopharmaceutical company’s stock worth $1,517,000 after purchasing an additional 2,284 shares during the last quarter. First Fiduciary Investment Counsel Inc. increased its position in shares of Pfizer by 2.1% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 237,043 shares of the biopharmaceutical company’s stock worth $5,746,000 after purchasing an additional 4,928 shares during the last quarter. Strengthening Families & Communities LLC grew its position in Pfizer by 871.3% during the second quarter. Strengthening Families & Communities LLC now owns 2,370 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,126 shares during the last quarter. Finally, Blue Trust Inc. grew its position in Pfizer by 3.1% during the second quarter. Blue Trust Inc. now owns 118,351 shares of the biopharmaceutical company’s stock valued at $2,869,000 after acquiring an additional 3,548 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $24.81 on Friday. The firm has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.83 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business has a 50 day moving average price of $24.86 and a 200-day moving average price of $24.14.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PFE shares. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.